Anzeige
Mehr »
Freitag, 21.11.2025 - Börsentäglich über 12.000 News
Europa im Fokus: Die Lage spitzt sich zu - und ein Player profitiert
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41556 | ISIN: US87978U2078 | Ticker-Symbol: 3OS0
Lang & Schwarz
20.11.25 | 07:00
6,010 Euro
-100,00 % -6,010
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
TEMPEST THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TEMPEST THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,9206,10020.11.

Aktuelle News zur TEMPEST THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiTempest Therapeutics: Aktie bricht nach reiner Aktienübernahme ein26
MiTempest Therapeutics to acquire Factor Bioscience's CAR-T programs17
MiTempest Therapeutics: Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027437All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T programAcquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR- Antagonist, Phase 3-ready) and TPST-1495...
► Artikel lesen
MiTempest Therapeutics, Inc. - 8-K, Current Report3
05.11.Tempest Therapeutics: Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update135BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated...
► Artikel lesen
05.11.Tempest Therapeutics, Inc. - 10-Q, Quarterly Report4
TEMPEST THERAPEUTICS Aktie jetzt für 0€ handeln
05.11.Tempest Therapeutics, Inc. - 8-K, Current Report1
11.08.Tempest Therapeutics GAAP EPS of -$2.07 beats by $0.5822
11.08.Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update585Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines...
► Artikel lesen
11.08.Tempest Therapeutics, Inc. - 10-Q, Quarterly Report6
11.08.Tempest Therapeutics, Inc. - 8-K, Current Report6
30.06.Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China527Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest...
► Artikel lesen
12.06.Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor17
11.06.Tempest Therapeutics: Tempest Announces $4.6 Million Registered Direct Offering of Common Stock3
11.06.Tempest Therapeutics announces $4.6 million registered direct offering1
06.06.Tempest Therapeutics, Inc. - 8-K, Current Report16
06.06.TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy16
05.06.Tempest Therapeutics-Aktie steigt nach EMA-Orphan-Drug-Designation12
05.06.Tempest Therapeutics stock rises on EMA Orphan Drug Designation5
05.06.Tempest Therapeutics: European Medicines Agency Grants Orphan Drug Designation To Amezalpat4
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1